<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836858</url>
  </required_header>
  <id_info>
    <org_study_id>CCMK389B12201</org_study_id>
    <secondary_id>2020-003406-31</secondary_id>
    <nct_id>NCT04836858</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.</brief_title>
  <official_title>A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this phase 2 study is to assess the efficacy and safety of CMK389 in&#xD;
      patients with atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Investigator Global assessment (IGA) response at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>To assess the efficacy of CMK389 in participants with moderate to severe AD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>Up to Week 32 (end of study)</time_frame>
    <description>To assess the safety and tolerability of CMK389 in participants with AD</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>CMK389 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo high dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMK389 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo low dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMK389</intervention_name>
    <description>Active</description>
    <arm_group_label>CMK389 high dose</arm_group_label>
    <arm_group_label>CMK389 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo high dose</arm_group_label>
    <arm_group_label>Placebo low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female participants with chronic atopic dermatitis, aged 18 to 65 years,&#xD;
             present for at least 1 year before screening.&#xD;
&#xD;
          -  Participants with Moderate to severe AD defined by IGA score of ≥ 3 (on a scale of 0&#xD;
             to 4, in which 3 is moderate and 4 is severe) at Baseline, EASI score of ≥ 12 at&#xD;
             Baseline and Pruritus (NRS) of at least ≥ 3 at Baseline&#xD;
&#xD;
          -  Participants who are candidates for a systemic therapy, defined as e.g. inadequate&#xD;
             response to treatment with topical medications, or for whom topical treatments are&#xD;
             otherwise medically inadvisable (e.g. because of important side effects or safety&#xD;
             risks, patients with large affected body surface areas) as assessed by the&#xD;
             investigator.&#xD;
&#xD;
          -  Participants must have a body mass index (BMI) at screening within the range of 18 to&#xD;
             ≤35 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any skin disease that, in the opinion of the investigator, would confound the&#xD;
             diagnosis or evaluation of AD disease activity.&#xD;
&#xD;
          -  Participants taking prohibited medication not completing the wash out period&#xD;
&#xD;
          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives&#xD;
             of enrollment, or until the expected PD effect has returned to baseline, whichever is&#xD;
             longer; or longer if required by local regulations.&#xD;
&#xD;
          -  Any active, recent or recurrent systemic or localized infection at screening or prior&#xD;
             to first treatment which in the opinion of the investigator immunocompromises the&#xD;
             participant and/or places the participant at unacceptable risk for immunomodulatory&#xD;
             therapy, that has not resolved within 2 weeks prior to first treatment or within 12&#xD;
             months in case of ezcema herpeticum, Clinically infected AD within 4 weeks prior to&#xD;
             first treatment, TB, HIV, Hepatitis B and C.&#xD;
&#xD;
          -  Any other current or past clinically significant medical condition, including&#xD;
             psychiatric condition, which in the Investigator's opinion may interfere with safety&#xD;
             of the participant, study objectives or adherence to the protocol.&#xD;
&#xD;
          -  Participants with confirmed abnormal absolute neutrophil count (ANC) of &lt;1.5 x 109/L&#xD;
             or with thrombocytopenia of &lt; 75.0 x 109/L at screening and baseline&#xD;
&#xD;
          -  History of malignancy of any organ system (other than localized basal cell carcinoma&#xD;
             of the skin), treated or untreated, within the past 5 years, regardless of whether&#xD;
             there is evidence of local recurrence or metastases.&#xD;
&#xD;
          -  History of hypersensitivity to any component of the study drug product, or to drugs of&#xD;
             similar chemical classes.&#xD;
&#xD;
          -  History of severe or serious allergy or hypersensitivity reactions, such as&#xD;
             anaphylactic shock, asthma, or uncontrolled urticaria.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <state>Czech Republic</state>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Bentheim</city>
        <zip>48455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35 055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Atopic Eczema</keyword>
  <keyword>Eczema</keyword>
  <keyword>CMK389</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

